Derived from Cistus x incanus L. Pandalis, the extract Cystus Pandalis® has been subject to several examinations concerning its antiviral effect. Its effectiveness has been proven in all examinations in-vitro and in-vivo. In physiological dosages, the Infection of cell cultures by applied viruses was completely prevented in-vitro without the cells being affected by Cystus Pandalis® extract. Likewise, the application of Cystus Pandalis® extract in-vivo showed that it prevented the infection of subjects, in contrast to subjects of the control group living in similar life situations. The effect is based presumebly on the specific highly concentrated polyphenols typical to the variety in the used extract. Its dense concentration of polymeric polyphenols (over 90%) in contrast to its relativeley low content of monomeric polyphenols (about 2%) seems to be key to this specific extract. So it blocks the cellular attachment sites and inhibits the virus from entering. As it is for SARS-CoV-2, it seems plausible that the extract encases surface proteins (in this case the Spike-Protein) to prevent the virus from attaching to the human cell and, therefore, avert infection. Cystus Pandalis® extract is available as lozenges or mouthrinse in form of a decoction. Prophylactic use during infectious waves and viral epidemics/pandemics at any stage is easily feasible. The extract is well-tolerated and has caused no known sideeffects. So far, no viral resistances or the development thereof have been detected. In Addition, no contraindications or interactions with other drugs are known to date. Cystus Pandalis® extract is freely available and can be applied regardless of age or sex.
| Published in | Journal of Diseases and Medicinal Plants (Volume 7, Issue 4) |
| DOI | 10.11648/j.jdmp.20210704.13 |
| Page(s) | 109-118 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Cystus Pandalis®, Virus Infection, SARS-CoV-2, Antiviral, Cistus Incanus, Pathogens
| [1] | Powner, M., Gerland, B. & Sutherland, J.: Synthesis of activated pyrimidine ribonucleotides in prebiotically plausible conditions. Nature 459, 239–242. https://doi.org/10.1038/nature08013 (2009). |
| [2] | Nutman AP et al.: Rapid emergence of life shown by discovery of 3,700-million-year-old microbial structures Nature 537, pages 535–538 https://doi.org/10.1038/nature19355 (2016). |
| [3] | How the Flu Virus Can Change ‘Drift’ and ‘Shift’. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD) https://www.cdc.gov/flu/about/viruses/change.htm; last viewed September 21st, 2021. (2021). |
| [4] | DAZ: Mutanten und Virusevolution - Kann Impfen Resistenzen fördern? https://www.deutsche-apotheker-zeitung.de/news/artikel/2021/03/31/kann-impfen-resistenzen-foerdern/chapter:1 last viewed: March 31st 2021 (2021). |
| [5] | Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R.: Viral mutation rates. J Virol. 2010 Oct; 84 (19): 9733-48. doi: 10.1128/JVI.00694-10. Epub 2010 Jul 21. (2021). |
| [6] | Van Egeren D, Novokhodko A, Stoddard M, Tran U, Zetter B, et al.: Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein. PLOS ONE 16 (4): e0250780. https://doi.org/10.1371/journal.pone.0250780. (2021). |
| [7] | Read AF, Baigent SJ, Powers C, Kgosana LB, Blackwell L, et al.: Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens. PLOS Biology 13 (7): e1002198. https://doi.org/10.1371/journal.pbio.1002198. (2015). |
| [8] | Pott R: Polymorphismus bei Cistrosen: Welche Varietaet ist als Heilmittel tauglich? KFN-Pressekonferenz, Vortrag, November 11th 2006 (2006). |
| [9] | Petereit F. Polyphenolische Inhaltsstoffe und Untersuchungen zur entzuendungshemmenden Aktivitaet der traditionellen Arzneipflanze Cistus incanus L. (Cistaceae). Dissertation, Universität Muenster, 1992. (1992). |
| [10] | Ehrhardt C, Hrincius ER, Korte V, Mazur I, Droebner K, et al.: A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. Antiviral research 2007, 76 (1), 38-47. doi: 10.1016/j.antiviral.2007.05.002 (2007). |
| [11] | Riehle P: Phenolische Inhaltsstoffe in C. incanus Tee – Charakterisierung und Stabilitaet innerhalb der Teezubereitung. Dissertation Universitaet Hamburg (2014). |
| [12] | Xu J, Xu Z, Zheng W. A Review of the Antiviral Role of Green Tea Catechins. Molecules. 2017; 22 (8): 1337. Published 2017 Aug 12th. (2017). |
| [13] | Williamson MP, McCormick TG, Nance CL, Shearer WT. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy. J Allergy Clin Immunol. 2006 Dec; 118 (6): 1369-74. (2006). |
| [14] | Rebensburg S, Helfer M, Schneider M, Koppensteiner H, Eberle J, et al.: Potent in vitro antiviral activity of Cistus incanus extract against HIV and Filoviruses targets viral envelope proteins. Scientific reports 2016, 6, 20394. doi: 10.1038/srep20394 (2016). |
| [15] | Song JM, Lee KH, Seong BL. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res. 2005 Nov; 68 (2): 66-74. (2005). |
| [16] | Mhatre S, Srivastava T, Naik S, Patravale V. Antiviral activity of green tea and black tea polyphenols in prophylaxis and treatment of COVID-19: A review [published online ahead of print, 2020 Jul 17]. Phytomedicine. 2020; 153286. (2020). |
| [17] | Droebner K, Haasbach E, Mueller C, Ludwig S, & Planz O. The polyphenol rich plant extract CYSTUS052 is highly effective against H5N1 and pandemic H1N1v influenza A virus. Influenza and Other Respiratory Viruses 2011, 5, 237-239. doi: 10.1111/j.1750-2659.2011.00209.x (2001). |
| [18] | Traeder JM. Antivirale Eigenschaften des Extrakts aus Cistus×incanus L. Pandalis auch bei SARS-CoV-2 in vitro nachgewiesen. Zeitschrift für Phytotherapie 2021; 42 (03): 121-126, DOI: 10.1055/a-1302-6097 (2021). |
| [19] | Traeder JM. Extract from Cistus × Incanus L. Pandalis also Effective against ‘British’ Alpha (B.1.1.7) and ‘South African’ Beta (B.1.351) SARS-CoV-2 Variants, Journal of Diseases and Medicinal Plants. Vol. 7, No. 2, 2021, pp. 44-47. doi: 10.11648/j.jdmp.20210702.13 (2021). |
| [20] | Droebner K, Ehrhardt C, Poetter A, Ludwig S, & Planz O.: CYSTUS052, a polyphenol-rich plant extract, exerts anti-influenza virus activity in mice. Antiviral research 2007, 76 (1), 1-10. doi: 10.1016/j.antiviral.2007.04.001 (2007). |
| [21] | Kalus U, Grigorov A, Kadecki O, Jansen JP, Kiesewetter H, et al.: Cistus incanus (CYSTUS052) for treating patients with infection of the upper respiratory tract: a prospective, randomised, placebo-controlled clinical study. Antiviral research 2009, 84 (3), 267-271. doi: 10.1016/j.antiviral.2009.10.001 (2009). |
| [22] | Kalus U, Kiesewetter H, Radtke H.: Effect of CYSTUS052 and green tea on subjective symptoms in patients with infection of the upper respiratory tract. Phytother Res. 2010 Jan; 24 (1): 96-100. doi: 10.1002/ptr.2876. PMID: 19444821. (2010). |
| [23] | Guendling PW, dos Santos P: Schach den Antibiotika - Phytotherapie bei Atemwegserkrankungen. Erkenntnisse aus der Praxis, Phytotherapiekongress Muenster, 20.09.2019 (2019). |
| [24] | Adler M. Retrolektive Therapiebeobachtung im Rahmen der Pandemie mit Covid-19. Zeitschrift fuer Phytotherapie 2020; 41 (03): 111-112. doi: 10.1055/a-1102-1686 (2020). |
| [25] | Traeder JM: Cistus × Incanus L. Pandalis is Highly Effective against Delta Variant of SARS-CoV-2 in Vitro. Journal of Diseases and Medicinal Plants. Volume 7, Issue 3, September 2021, Pages: 82-86. doi: 10.11648/j.jdmp.20210703.13 (2021). |
| [26] | Bader M: ACE2 – the hijacked all-rounder. Nephrologe. 2020 Jul 15: 1-4. doi: 10.1007/s11560-020-00448-0 [Epub ahead of print] (2020). |
| [27] | Bubenzer, RH: Cistus-incanus-Tee. Hoher Polyphenolgehalt Grund fuer hohe antioxidative Wirkung. Heilpflanzen-Welt.de, August 2014. https://www.heilpflanzen-welt.de/2015-03-Cistus-incanus-Tee-Hoher-Polyphenolgehalt-Grund-fuer-hohe-antioxidative-Wirkung (2015). |
APA Style
Jens-Martin Traeder. (2021). Cistus × Incanus L. Pandalis and Its Broad Antiviral Properties. Journal of Diseases and Medicinal Plants, 7(4), 109-118. https://doi.org/10.11648/j.jdmp.20210704.13
ACS Style
Jens-Martin Traeder. Cistus × Incanus L. Pandalis and Its Broad Antiviral Properties. J. Dis. Med. Plants 2021, 7(4), 109-118. doi: 10.11648/j.jdmp.20210704.13
AMA Style
Jens-Martin Traeder. Cistus × Incanus L. Pandalis and Its Broad Antiviral Properties. J Dis Med Plants. 2021;7(4):109-118. doi: 10.11648/j.jdmp.20210704.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.jdmp.20210704.13,
author = {Jens-Martin Traeder},
title = {Cistus × Incanus L. Pandalis and Its Broad Antiviral Properties},
journal = {Journal of Diseases and Medicinal Plants},
volume = {7},
number = {4},
pages = {109-118},
doi = {10.11648/j.jdmp.20210704.13},
url = {https://doi.org/10.11648/j.jdmp.20210704.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jdmp.20210704.13},
abstract = {Derived from Cistus x incanus L. Pandalis, the extract Cystus Pandalis® has been subject to several examinations concerning its antiviral effect. Its effectiveness has been proven in all examinations in-vitro and in-vivo. In physiological dosages, the Infection of cell cultures by applied viruses was completely prevented in-vitro without the cells being affected by Cystus Pandalis® extract. Likewise, the application of Cystus Pandalis® extract in-vivo showed that it prevented the infection of subjects, in contrast to subjects of the control group living in similar life situations. The effect is based presumebly on the specific highly concentrated polyphenols typical to the variety in the used extract. Its dense concentration of polymeric polyphenols (over 90%) in contrast to its relativeley low content of monomeric polyphenols (about 2%) seems to be key to this specific extract. So it blocks the cellular attachment sites and inhibits the virus from entering. As it is for SARS-CoV-2, it seems plausible that the extract encases surface proteins (in this case the Spike-Protein) to prevent the virus from attaching to the human cell and, therefore, avert infection. Cystus Pandalis® extract is available as lozenges or mouthrinse in form of a decoction. Prophylactic use during infectious waves and viral epidemics/pandemics at any stage is easily feasible. The extract is well-tolerated and has caused no known sideeffects. So far, no viral resistances or the development thereof have been detected. In Addition, no contraindications or interactions with other drugs are known to date. Cystus Pandalis® extract is freely available and can be applied regardless of age or sex.},
year = {2021}
}
TY - JOUR T1 - Cistus × Incanus L. Pandalis and Its Broad Antiviral Properties AU - Jens-Martin Traeder Y1 - 2021/11/24 PY - 2021 N1 - https://doi.org/10.11648/j.jdmp.20210704.13 DO - 10.11648/j.jdmp.20210704.13 T2 - Journal of Diseases and Medicinal Plants JF - Journal of Diseases and Medicinal Plants JO - Journal of Diseases and Medicinal Plants SP - 109 EP - 118 PB - Science Publishing Group SN - 2469-8210 UR - https://doi.org/10.11648/j.jdmp.20210704.13 AB - Derived from Cistus x incanus L. Pandalis, the extract Cystus Pandalis® has been subject to several examinations concerning its antiviral effect. Its effectiveness has been proven in all examinations in-vitro and in-vivo. In physiological dosages, the Infection of cell cultures by applied viruses was completely prevented in-vitro without the cells being affected by Cystus Pandalis® extract. Likewise, the application of Cystus Pandalis® extract in-vivo showed that it prevented the infection of subjects, in contrast to subjects of the control group living in similar life situations. The effect is based presumebly on the specific highly concentrated polyphenols typical to the variety in the used extract. Its dense concentration of polymeric polyphenols (over 90%) in contrast to its relativeley low content of monomeric polyphenols (about 2%) seems to be key to this specific extract. So it blocks the cellular attachment sites and inhibits the virus from entering. As it is for SARS-CoV-2, it seems plausible that the extract encases surface proteins (in this case the Spike-Protein) to prevent the virus from attaching to the human cell and, therefore, avert infection. Cystus Pandalis® extract is available as lozenges or mouthrinse in form of a decoction. Prophylactic use during infectious waves and viral epidemics/pandemics at any stage is easily feasible. The extract is well-tolerated and has caused no known sideeffects. So far, no viral resistances or the development thereof have been detected. In Addition, no contraindications or interactions with other drugs are known to date. Cystus Pandalis® extract is freely available and can be applied regardless of age or sex. VL - 7 IS - 4 ER -
Information
Email: